Phase 2 Obesity trials recruiting now

All Obesity trials, every phase

Other phases for Obesity

Phase 2 Obesity trials

• A Clinical Trial Using Tirzepatide to Help Adults With Type 1 Diabetes Automatically Control Their Blood Sugar
  NCT07284511 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• A First-In-Human Study of ARO-ALK7 in Adults With Obesity With and Without Type 2 Diabetes Mellitus
  NCT06937203 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 16 locations
• A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus
  NCT06700538 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 7 locations
• A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
  NCT06143956 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 56 locations
• A Mobile Intervention to Reduce Pain and Improve Health-III
  NCT06623669 · Phase: Phase 2 · Ages: 65 Years and older · Sex: All (male and female) · 1 location
• A Novel Obesity Prevention Program for High-Risk Infants in Primary Care
  NCT06028113 · Phase: Phase 2 · Ages: 1 Day and older · Sex: All (male and female) · 1 location
• A Phase 1/2a Study of WVE-007 in Adults Living With Overweight or Obesity
  NCT06842186 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 60 Years · Sex: All (male and female) · 6 locations
• A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors
  NCT07656727 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 13 locations
• A Phase 2A Clinical Trial to Assess the Safety and Tolerability of ERX1000 in Men and Women for the Treatment of Obesity.
  NCT07570758 · Phase: Phase 2 · Ages: 18 Years to 60 Years · Sex: All (male and female) · 3 locations
• A Phase I/IIa Clinical Study to Assess the Single and Multiple Ascending Doses of MDR-001 Tablets in Healthy Participants and Obese/ Overweight Participants
  NCT06778850 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 55 Years · Sex: All (male and female) · 1 location
• A Phase Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity
  NCT07243171 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity
  NCT07639021 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 25 locations
• A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease
  NCT06717698 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 147 locations
• A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity
  NCT07395687 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 3 locations
• A Self-Guided Mobile Intervention for Adults With Binge Eating and Obesity
  NCT06817863 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• A Study of BGM0504 in Participants With Obesity
  NCT06911203 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• A Study of CSTI-500 in Patients With Prader-Willi Syndrome
  NCT07348601 · Phase: Phase 2 · Ages: 13 Years to 50 Years · Sex: All (male and female) · 1 location
• A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With Obesity
  NCT06862908 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
  NCT06897475 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 60 locations
• A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetes
  NCT06924320 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 2 locations
• A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
  NCT07215559 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 42 locations
• A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity (SOLIS-1)
  NCT07575932 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 65 locations
• A Study of RAY1225 in Participants With Obesity
  NCT06254261 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment
  NCT06239116 · Phase: Phase 1, Phase 2 · Ages: 12 Years to 65 Years · Sex: All (male and female) · 7 locations
• A Study of the Effect of (S)-Pindolol Benzoate (ACM-001.1) on Lean Body Mass (LBM) in Obese Patents During (PROACT 1), and Post-semaglutide Therapy (PROACT 2)
  NCT07101939 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 7 locations
• A Study to Assess the Efficacy, Safety and Tolerability of AT673 Co-administered With Semaglutide in Adult Participants With Type 2 Diabetes (T2D) and Overweight or Obesity
  NCT07724340 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 8 locations
• A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial Neoplasia
  NCT07107334 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 1 location
• A Study to Evaluate ALN-2232 in Participants With Obesity
  NCT07463846 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH)
  NCT06836609 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 4 locations
• A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
  NCT07589608 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 40 locations
• A Study to Investigate the Efficacy and Safety of Two Different Doses of Twice Daily Distal Jejunal-release Dextrose Beads Formulations Combined With a Gel Composition Compared to Placebos in Obese Subjects With Weight Related Comorbidities
  NCT07008456 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 6 locations
• A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia
  NCT07477704 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 34 locations
• A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweight
  NCT07662122 · Phase: Phase 2 · Ages: 18 Years to 74 Years · Sex: All (male and female) · 55 locations
• A Three-part First-in-human Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GUB-UCN2 in Healthy Lean and Obese Participants and Participants With T2D
  NCT07702890 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight
  NCT07441252 · Phase: Phase 2 · Ages: 18 Years to 99 Years · Sex: All (male and female) · 23 locations
• Anti Inflammatory Lipid Mediators in Asthma Lipid Anti-Inflammtory Mediators in Asthma
  NCT03762395 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• Antibiotic Prophylaxis to Prevent Obesity-Related Induction Complications in Nulliparae at Term 2.0
  NCT06488781 · Phase: Phase 2 · Ages: 15 Years to 45 Years · Sex: Female · 1 location
• Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity
  NCT06745063 · Phase: Phase 2 · Ages: 30 Years to 60 Years · Sex: All (male and female) · 1 location
• Atomoxetine in Melanocortin Obesity Syndrome
  NCT06899178 · Phase: Phase 2 · Ages: 6 Years and older · Sex: All (male and female) · 3 locations
• Bariatric Endoscopic Antral Myotomy Combined With Fundal Gastric Mucosal Ablation
  NCT07612527 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Bariatric Surgery Combined With GLP-1 Receptor Agonists Study
  NCT07336862 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 60 Years · Sex: All (male and female) · 1 location
• Bone Metabolism in 12-21 Year Olds Undergoing Glucagon Like Peptide (GLP)-1 Receptor Agonist Therapy
  NCT06903923 · Phase: Phase 2 · Ages: 12 Years to 21 Years · Sex: All (male and female) · 1 location
• Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
  NCT05082519 · Phase: Phase 2 · Ages: 7 Years to 25 Years · Sex: All (male and female) · 16 locations
• Cannabis for Obesity Trial
  NCT06137365 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• Comparative Clinical and Biochemical Study Evaluating the Effectiveness of Metformin Versus Febuxostat on Gouty Obese Non-Diabetic Patients
  NCT06995339 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• Control Systems Engineering for Weight Loss Maintenance
  NCT06244888 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• Convergent Mechanisms Underlying Reprometabolic Syndrome in Women
  NCT06686537 · Phase: Phase 2 · Ages: 18 Years to 38 Years · Sex: Female · 2 locations
• Determining the Optimal Amount of Structured Environments for Healthy Kids
  NCT06158594 · Phase: Phase 2 · Ages: 5 Years to 12 Years · Sex: All (male and female) · 1 location
• EXploratory Study on Postprandial Energy Metabolism
  NCT06786052 · Phase: Phase 2 · Ages: 50 Years to 70 Years · Sex: All (male and female) · 1 location
• Effect of Empagliflozin on Metabolic Outcomes in Adults Living With HIV Receiving Dolutegravir-Based Therapy
  NCT07336797 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• Effect of Ketone Esters on Liver Fat Content and Metabolic Function
  NCT07097506 · Phase: Phase 2 · Ages: 18 Years to 40 Years · Sex: All (male and female) · 1 location
• Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are Overweight
  NCT07467447 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Effect of Tirzepatide and Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults With Obesity
  NCT05933499 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Effect of Weight Loss on Physical and Cardiac Performance in People With Obesity and Heart Failure
  NCT06423599 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Effects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults
  NCT06811324 · Phase: Phase 2 · Ages: 50 Years and older · Sex: All (male and female) · 1 location
• Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes
  NCT06762314 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• Efficacy and Safety of GL0034 in Overweight or Obese Adults With Type II Diabetes Mellitus
  NCT07282743 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 21 locations
• Efficacy and Safety of HDM1005 Compared to Tirzepatide in Obese Adults Without Diabetes
  NCT07521631 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• Efficacy and Safety of KBP-336 in Obese Individuals with Osteoarthritis
  NCT06833749 · Phase: Phase 2 · Ages: 45 Years and older · Sex: All (male and female) · 20 locations
• Efficacy and Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Overweight With at Least 1 Weight-Related Comorbidity
  NCT07497880 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 36 locations
• Efficacy and Safety of Phentermine/Topiramate in Youth With Hypothalamic Obesity
  NCT06299891 · Phase: Phase 2 · Ages: 6 Years to 28 Years · Sex: All (male and female) · 2 locations
• Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder
  NCT06847399 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• FIM+DASH: Food is Medicine Intervention to Promote Healthy Eating and Blood Pressure Control
  NCT07332741 · Phase: Phase 2 · Ages: No age limits stated · Sex: All (male and female) · 8 locations
• Fasted vs. Fed State Exercise
  NCT07487090 · Phase: Phase 2 · Ages: 18 Years to 59 Years · Sex: All (male and female) · 1 location
• Feasibility of Semaglutide in Advanced Lung Disease
  NCT05746039 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• Food Effect, Efficacy and Safety of MKP10241 in Healthy and Obese Adult Participants, With and Without Diabetes
  NCT07098663 · Phase: Phase 2 · Ages: 18 Years to 60 Years · Sex: All (male and female) · 1 location
• Food-Body-Mind Intervention (16 Weeks)
  NCT06597474 · Phase: Phase 2, Phase 3 · Ages: 3 Years to 5 Years · Sex: All (male and female) · 1 location
• Glucagon-Like Peptide-1 Receptor Agonist in ADPKD
  NCT06582875 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients
  NCT05316935 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 45 Years · Sex: Female · 2 locations
• GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients
  NCT06379113 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 45 Years · Sex: Female · 2 locations
• HS235 Study in Obese Participants With Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction (HFpEF)
  NCT07123779 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• Healthy Kids Beyond the Bell: Investigating the Impact of After-School and Summer Programs
  NCT05880901 · Phase: Phase 2 · Ages: 5 Years to 12 Years · Sex: All (male and female) · 1 location
• Incretin Microdosing for Cardiometabolic Health in People With HIV
  NCT07325500 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Integrated Traditional Chinese Medicine Day Care Program for Metabolic Syndrome
  NCT06703788 · Phase: Phase 1, Phase 2 · Ages: 20 Years to 75 Years · Sex: All (male and female) · 1 location
• Investigating Whether Acute Elevation of Fatty Acid Levels Alters Cerebral Glucose Transport and Metabolism
  NCT04328337 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 45 Years · Sex: All (male and female) · 2 locations
• Ketorolac and Pregabalin Effects on breaSt Cancer (KePreSt)
  NCT06150898 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity
  NCT07505745 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• Metformin IN Asthma for Overweight and Obese Individuals (MINA)
  NCT06273072 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Obesity Complicating Type 1 Diabetes: GLP-1 Analogue Anti-obesity Treatment
  NCT06411210 · Phase: Phase 2 · Ages: 18 Years to 30 Years · Sex: All (male and female) · 1 location
• Oxytocin for Weight Loss in Adolescents
  NCT04551482 · Phase: Phase 2 · Ages: 10 Years to 18 Years · Sex: All (male and female) · 1 location
• PRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis
  NCT04971720 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Pharmacokinetics of Drospirenone Only Pills: A Pre- and Post-Bariatric Surgery Study
  NCT06345560 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 45 Years · Sex: Female · 1 location
• Pharmacologic Weight Loss as Adjunct Therapy for Ulcerative Colitis in Obese Patients
  NCT04721873 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• Phase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effect on Body Weight of RN3161 as Monotherapy and in Combination With Tirzepatide in Adults With Overweight and Obesity
  NCT07245771 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• Phase II Clinical Study of HDM1005 Injection in Obese Adults Without Diabetes Mellitus
  NCT06886126 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• Phase II Study of THDBH120 Injection in Overweight or Obese Subjects
  NCT07036601 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Phentermine's Impact on Treatment in Teens
  NCT07282340 · Phase: Phase 2 · Ages: 12 Years to 17 Years · Sex: All (male and female) · 6 locations
• Photobiomodulation in Chronic Knee Pain in Patients Who Are in PreRehabilitation for Bariatric Surgery
  NCT05816798 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• Pilot Testing a Novel Approach to Pediatric Obesity Treatment
  NCT06755827 · Phase: Phase 1, Phase 2 · Ages: 11 Years to 14 Years · Sex: All (male and female) · 1 location
• Probiotics and Gut Health
  NCT03418857 · Phase: Phase 1, Phase 2 · Ages: 55 Years to 75 Years · Sex: All (male and female) · 1 location
• Project SHINE (Sleep Health INitiative for Equity): Culturally Informing a Sleep Extension Intervention for African American Adults
  NCT06226077 · Phase: Phase 1, Phase 2 · Ages: 21 Years to 75 Years · Sex: All (male and female) · 1 location
• Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss
  NCT07446998 · Phase: Phase 2 · Ages: 65 Years to 100 Years · Sex: All (male and female) · 14 locations
• Resistance Exercise and Incretin Mimetic for Cardiometabolic Health in Survivors of ALL With Obesity
  NCT07228741 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
  NCT07752979 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 40 locations
• Semaglutide for Post-Smoking Cessation Weight Management
  NCT06173778 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 2 locations
• Semaglutide in Women With Polycystic Ovary Syndrome and Obesity
  NCT06896981 · Phase: Phase 2, Phase 3 · Ages: 10 Years to 45 Years · Sex: Female · 2 locations
• Single Nuclei RNA-seq to Map Adipose Cellular Populations and Senescent Cells in Older Subjects
  NCT05653258 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Sit Less, Interact and Move More (SLIMM) 2 Study
  NCT05173714 · Phase: Phase 2 · Ages: 20 Years and older · Sex: All (male and female) · 4 locations
• Social Determinants and a Diabetes Prevention Program Tailored for African Americans
  NCT05301413 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes
  NCT07685808 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 5 locations

Showing 100 of 122 recruiting trials.

Common questions

What does Phase 2 mean?

See how clinical trials work.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.